Page 211 - 2021_05-Haematologica-web

Effects of absence of PTGS1 in platelets
HEA) and National Institute for Health Research (ACF to SS, Biomedical Research Centres (BRC) 2017-2022: Population and Quantitative Science to DG and ET). This work was supported, in part, by the Division of Intramural Research, National Institute of Environmental Health Sciences, NIH (Z01 ES025034 to DCZ). VBO is also a Royal Society Wolfson Merit Award Holder and is further supported by the Wellcome Trust
(094143/Z/10/Z) and European Research Council (LipidArrays). This work was supported by National Institutes of Health grant R01 GM115386 (MGM). KD is supported as a HSST trainee by Health Education England. KF is supported by CSL Behring, Bayer and SOBI Chairs and Research Council of the University of Leuven (BOF KU Leuven‚ Belgium, OT/14/098).
References
1.Allen RD, Zacharski LR, Widirstky ST, Rosenstein R, Zaitlin LM, Burgess DR. Transformation and motility of human platelets. Details of the shape change and release reaction observed by optical and electron microscopy. J Cell Biol. 1979; 83(1):126-142.
2. Bearer EL, Prakash JM, Li Z. Actin dynam- ics in platelets. Int Rev Cytol. 2002; 217:137-182.
3. Brass LF, Wannemacher KM, Ma P, Stalker TJ. Regulating thrombus growth and stabil- ity to achieve an optimal response to injury. J Thromb Haemost. 2011;9(1):66-75.
4.Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69(1):145-182.
5.Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271(52):33157-33160.
6. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chemical Rev. 2011;111(10):5821-5865.
7.Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.
8. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676-688.
9. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relation- ships among dose, effectiveness, and side effects. Chest. 2004;126(3):234S-264S.
10. Warner TD, Nylander S, Whatling C. Anti- platelet therapy: cyclo-oxygenase inhibi- tion and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 2011;72(4):619-633.
11. Jaffe EA, Weksler BB. Recovery of endothe- lial cell prostacyclin production after inhibi- tion by low doses of aspirin. J Clin Invest 1979;63(3):532-535.
12.Westbury SK, Turro E, Greene D, et al. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Med. 2015;7(1):36.
13.Ouwehand WH, Gräf S, Tilly T, Swietlik EM, Morrell NW. Whole-genome sequenc- ing of rare disease patients in a national healthcare system. BioRxiv. 2020 Jan 17. [Epub ahead of print]
14.Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-5467.
15.Vecchio AJ, Simmons DM, Malkowski MG. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem.
2010;285(29):22152-22163.
Identification and functional characteriza- tion of polymorphisms in human cyclooxy- genase-1 (PTGS1). Pharmacogenet Genomics. 2007;17(2):145-160.
32. Loftin CD, Tiano HF, Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiolog- ical roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002; 68-69:177-185.
33.Paknikar AK, Eltzner B, Köster S. Direct characterization of cytoskeletal reorganiza- tion during blood platelet spreading. Prog Biophys Mol Biol. 2019;144:166-176.
34.Hochman R, Clark J, Rolla A, Thomas S, Kaldany A, D’elia JA. Bleeding in patients with infections: are antibiotics helping or hurting? Arch Intern Med. 1982; 142(8):1440-1442.
35.Harrison P, Mackie I, Mumford A, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011;155(1):30-44.
36. Greene D, Richardson S, Turro E. A fast association test for identifying pathogenic variants involved in rare diseases. Am J Hum Genet. 2017;101(1):104-114.
37. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/ery- throleukemia cell prostaglandin G/H syn- thase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991; 5(9):2304-2312.
38.Kirkby NS, Reed DM, Edin ML, et al. Inherited human group IVA cytosolic phos- pholipase A2deficiency abolishes platelet, endothelial, and leucocyte eicosanoid gen- eration. FASEB J. 2015;29(11):4568-4578.
39. Matijevic-Aleksic N, Mcphedran P, Wu KK. Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) defi- ciency. Br J Haematol. 1996;92(1):212-217.
40. Grosser T, Naji A, FitzGerald GA. Urinary prostaglandin metabolites: an incomplete reckoning and a flush to judgment. Circ Res. 2018;122(4):537-539.
41. Strandvik B, Svensson E, Seyberth HW. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fat Acids. 1996;55(6):419-425.
42. Ciabattoni G, Davi G, Collura M, et al. In vivo lipid peroxidation and platelet activa- tion in cystic fibrosis. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1195-1201.
43. Dubé JN, Drouin J, Aminian M, Plant MH, Laneuville O. Characterization of a partial prostaglandin endoperoxide H synthase-1 deficiency in a patient with a bleeding dis- order. Br J Haematol. 2001;113(4):878-885.
44. Fuse I, Ootsuka T, Hattori A, Mito M, Shibata A. Vascular thromboxane forma- tion in hemostasis mechanism: correlation between bleeding time and vascular TXB2 in a patient with congenital platelet cyclo- oxygenase deficiency. Int J Hematol. 1996;63(4):317-324.
45. Horellou MH, Lecompte T, Lecrubier C, et al. Familial and constitutional bleeding dis- order due to platelet cyclo‐oxygenase defi-
16. Mitchell JA, Knowles RB, Kidney transplantation in cytosolic phospholipase origins of urinary PGI-M Res. 2018;122(4):555-559.
17. Chan M V., Armstrong
Kirkby NS, Warner TD. Optical multichan- nel (optimul) platelet aggregometry in 96- well plates as an additional method of platelet reactivity testing. Platelets. 2011;22(7):485-494.
18. Chan M V, Warner TD. Standardised opti- cal multichannel (optimul) platelet aggre- gometry using high-speed shaking and fixed time point readings. Platelets. 2012; 23(5):404-408.
20. Kircher M, Witten DM, Jain P, O’roak BJ, Cooper GM, Shendure J. A general frame- work for estimating the relative patho- genicity of human genetic variants. Nat Genet. 2014;46(3):310-315.
21.Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic varia- tion in 60,706 humans. Nature. 2016;536(7616):285-291.
22. Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabo- lites. J Biol Chem. 1981;256(16):8384-8393.
23. McFadyen JD, Peter K. Platelet lipidomics and function: Joining the dots. Blood. 2018; 132(5):465-466.
24. Cathcart M-C, Tamosiuniene R, Chen G, et al. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther. 2008;326(1):51-58.
25. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183- 1187.
26. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2016;4(6):CD001505.
27. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol. 1996;102:9-21.
28. Schubert S, Weyrich AS, Rowley JW. A tour through the transcriptional landscape of platelets. Blood. 2014;124(4):493-502.
29. Chan M V., Knowles RBMM, Lundberg MH, et al. P2Y12 receptor blockade syner- gizes strongly with nitric oxide and prosta- cyclin to inhibit platelet activation. Br J Clin Pharmacol. 2016;81(4):621-633.
30. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115(25):3156-3164.
31.Lee CR, Bottone FG, Krahn JM, et al.
19. Inoue O, Suzuki-Inoue
Frampton J, Watson SP. Integrin α 2 β 1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCγ2. J Cell Biol. 2003;160(5):769-780.
Kirkby NS, et al. a patient lacking A2proves renal and TX-M. Circ
PCJJ, Papalia F,
K, Dean
WL,
haematologica | 2021; 106(5)
1431